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KL-Grade n Mean
WOMAC
Pain, mm
(SD)
SEM min-max Mean
JSW
(mm)
n SEM min-max
(mm)
All 4299 212 (99) 1.5 0–500 3.71 4390 0.021 0–8.9
0 88 135 (105) 11.2 0–410 4.27 92 0.097 2.6–6.8
1 404 157 (104) 5.2 0–430 4.13 416 0.046 1.1–7.4
2 2904 211 (94) 1.7 0–500 3.97 2943 0.020 0–8.2
3 851 245 (94) 3.2 0–500 2.74 880 0.055 0–8.9
4 52 285 (109) 15.2 40–463 1.59 59 0.349 0–8.9
Table 1
Effect of MIV-711 on biomarkers of bone resorption and cartilage degradation in
PMW. Values given are mean %change from baseline. n ¼ 4 for placebo, n ¼ 8 for
MIV-711
Placebo MIV-711
Biomarker Day 1 Day 10 Day 28 Day 1 Day 10 Day 28
Serum CTX-I +14% +4% +20% 55% 65% 67%
Urine CTX-I +2% +20% 12% 81% 97% 98%
Urine NTX-I +8% +12% 7% 58% 73% 76%
Urine CTX-II +7% +7% +5% 49% 62% 55%
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ASSOCIATION BETWEEN JOINT SPACE WIDTH, KELLGREN-
LAWRENCE SCORE, PAIN AND PROGRESSION IN OSTEOARTHRITIS
SUBJECTS FROM TWO PHASE III STUDIES – A CLINICAL STUDY
REFERENCE DATABASE
P. Alexandersen y, I. Byrjalsen z, A.-C. Bay-Jensen z, A.-S. Siebur z,
J.R. Andersen z, B.J. Riis z, C. Christiansen z, M.A. Karsdal z. yCCBR, Vejle,
Denmark; zNordic BioSci., Herlev, Denmark
Purpose: Osteoarthritis (OA) disease severity is evaluated by
Kellgren-Lawrence score (KL-score) and Joint Space Width (JSW), as
well as patient-reported pain and function using the Western
Ontario and McMaster Universities Arthritis Index (WOMAC). For
clinical studies, in contrast to epidemiological background pop-
ulation studies, symptomatic OA patients are included, resulting in
signiﬁcant differences. There is a need for reference values for
clinical studies in OA. We pooled data from two phase III studies
resulting in the largest OA clinical trial dataset (N ¼ 2206). We
analyzed the association between JSW, KL-score, pain and JSN
(joint space narrowing) with the objective of providing further
information as how to select the optimal population for a clinical
OA trial.
Method: This is a post-hoc analysis of two randomized, double-blind,
multi-center, placebo-controlled trials (CSMC021C2301 and
CSMC021C2302), evaluating the efﬁcacy and safety of oral salmon cal-
citonin in subjects with painful knee OA. Subject enrollment period was
from May 2007 to August 2008 (N ¼ 1176) and from June 2008 to
December 2008 (N ¼ 1030). We analyzed pooled baseline data on KL-
score, pain and function metrics from the WOMAC questionnaire. The
main inclusion criteria for the target knee were 1: ACR OA criteria, 2:
KL-score: Grades II–III at the medial tibio-femoral joint, 3: American
Rheumatism Association criteria for classiﬁcation (ARA): Functional
class I, II or III, 4: JSW of 2.0 mm at medial tibio-femoral joint
(measured by X-ray), and 5: signiﬁcant pain, deﬁned as WOMAC pain
subscale (5 questions) result of 150 mm. Both target knee and the
contra-lateral knee, was analyzed, providing data from a total of 4390
knees. X-rays from 22 non-target knees were not available. Data was
stratiﬁed post-hoc for target vs.non-target knee. In the placebo-treated
subjects data was analysed for mean JSN during the trial period of two
years.
Results: Of the 2206 subjects 35% were males, the mean (SD) age was
64.4 (6.77) years and 88% were of Caucasian descent, 11.2% Asian and
0.6 % other. In the non-target knee, KL-score 0 to 4, KL-score and mean
WOMAC pain correlated signiﬁcantly (r ¼ 0.30; p < 0.0001). In the
analysis of all knees the mean JSW was virtually similar in subjects
with KL-scores 0–2, but was highly signiﬁcantly decreased in KL-
scores 3 and 4 (p < 0.0001, table). As expected in relation to the
selection criteria, subjects reported less mean (SEM)WOMAC pain in
the non-target knees than in the target knee (181  2.4 mm vs. 242 
1.6 mm, p < 0.0001), but only a slightly lower mean JSW (3.7  0.03
mm vs. 3.8  0.02 mm, p < 0.05) was observed. For knees with KL- 2
considerably less painwas reported in the non-target knees compared
to target knees (161  3.2 mm vs. 240  1.7 mm, respectively, p <
0.0001). The non-target knees also had a slightly higher JSW com-
pared to the target knee (4.1  0.03 mm vs. 3.9  0.03 mm, respec-
tively, p < 0.0001. For KL 3 knees, the pain was very similar in the
target and non-target knees (241 4.7 mm and 250 4.2 mm, p¼ NS)
but JSW was signiﬁcantly lower in non-target knees than the target
knees (2.5 0.08mmvs. 3.10.06 mm, respectively, p< 0.0001). This
last observation is related to the selection criteria of the protocol.
Overall, including all knees in the placebo group, the mean JSN pro-
gression was 0.321 mm  0.018 mm during the 2 year’s trial period. In
the non-target knee, mean JSN progression was 0.218  0.035 mm
over two years whereas it was 0.328  0.034 the target knee (p <
0.05).
Conclusion: These data from the largest clinical trial dataset in OA to
date clearly describe correlations between KL-score, JSW and pain in
patients with symptomatic knee OA. They provide clear background
material for designing future clinical trials in OA. As a key example, the
associations between pain and KL score were different in target versus
non-target knees. Patients with symptomatic OA at baseline progressed
signiﬁcantly faster than patients with asymptomatic disease. Further
research is needed to identify biomarkers for the description of the fast
progressors driven by different phenotypes, such as subchondral bone
turnover or inﬂammation driven progression.341
MIV-711, A HIGHLY SELECTIVE CATHEPSIN K INHIBITOR, REDUCES
BIOMARKERS OF BONE RESORPTION AND CARTILAGE
DEGRADATION IN HEALTHY SUBJECTS
E. Lindstrom, U. Grabowska, M. Jerling, C. Edenius. Medivir AB,
Huddinge, Sweden
Purpose: Excessive bone resorption and cartilage degradation are key
features of osteoarthritis (OA). Biomarkers reﬂecting these processes
are reduced in non-clinical studies performed with the selective cath-
epsin K inhibitor MIV-711. In addition, MIV-711 has provided structural
beneﬁt on bone and cartilage in animal models of OA. This abstract
presents results on biomarkers after multiple dosing as part of a First in
Man study with MIV-711.
Methods: A double-blind, placebo-controlled, randomized study in
27 healthy subjects of both genders. Multiple ascending doses of 50,
100 or 200 mg MIV-711 were given in the fasting state, once daily
for 7 days. An additional cohort consisting of 12 postmenopausal
women (PMW) dosed for 28 days with either placebo or 100 mg
MIV-711 once daily was also studied. Biomarkers reﬂecting cartilage
degradation (CTX-II) and bone resorption (CTX-I, NTX-I) were
measured.
Results: In the 7-day cohorts, MIV-711 decreased serum CTX-I
levels in a dose-dependent manner. At 24 h post ﬁnal dose, serum
CTX-I levels were reduced by 40%, 54% and 55% compared to
baseline in response to 50 mg, 100 mg and 200 mg MIV-711
respectively. By contrast, serum CTX-I levels were 6% higher in
placebo-treated subjects compared to baseline. Urinary levels of
CTX-II were also reduced in a dose-dependent fashion at this time
point by 31%, 58% and 72% vs. baseline, respectively. By contrast,
urine CTX-II levels were 30% higher in placebo-treated subjects on
Day 7 compared to baseline. After 28-day treatment in PMW,
serum CTX-I levels were reduced by 67% while urinary CTX-II levels
were reduced by 55% compared to baseline. In addition, urine
levels of CTX-I and NTX-I were reduced by 98% and 76% on Day 28
compared to baseline respectively. The time-course of these effects
on biomarkers and the comparison to placebo can be found in
Table 1 below. Overall, MIV-711 was safe and well tolerated over
the 28 day period.
Conclusions: Multiple doses of MIV-711 up to 200 mg adminis-
tered once daily to healthy subjects for 7 days produced dose-
dependent decreases in biomarkers of bone resorption and carti-
lage degradation. These results were conﬁrmed in 28 day studies
when given to PMW. MIV-711 was also safe and well-tolerated.
These data support the further development of MIV-711 for bone
and cartilage related disorders such as osteoporosis and osteo-
arthritis.
